Business
Shield Therapeutics (STX): All in the execution
Shield Therapeutics (STX): All in the execution.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nHardman & Co ResearchHardman & Co Research: Shield Therapeutics (STX): All in the execution13-May-2019 / 12:00 GMT/BST\nHardman & Co Research: All in the execution\n\nShield Therapeutics (AIM: STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency with Feraccru(R). Following IPO and EU approval of Feraccru, both in February 2016, STX has made good progress with its clinical and commercial strategy, most recently demonstrating in a phase 3 trial that oral Feraccru is as effective as intravenous iron. Management has secured commercialisation agreements and is now awaiting an FDA decision in 3Q'19. The remaining risks lie in US approval and in successful execution of commercialisation.\n\nPlease click here for the full report:\n\nhttps://www.hardmanandco.com/?post_type=research&p=2844&preview=true \n\nTo contact us:Hardman & Co35 New Broad StreetLondonEC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCo\n Contacts:Dr Martin HallDr Dorothea HillDr Gregoire Pave+44 20 7194 7622\n [email protected]@[email protected]\n \n \n\nHardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.\n\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\n\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticate...